ADALIMUMAB DOSE REDUCTION IN RHEUMATOID ARTHRITIS, PSORIATIC ARTHROPATHY AND ANKYLOSING SPONDYLITIS PATIENTS IN SUSTAINED CLINICAL REMISSION

被引：1

作者：

Borras-Blasco, J. ^{[1
]}

Gracia-Perez, A. ^{[2
]}

Antonio Perez-Torres, A. ^{[2
]}

Castera, D. -E. ^{[1
]}

Abad, J. ^{[1
]}

Rosique-Robles, D. ^{[1
]}

机构：

[1] Hosp Sagunto, Pharm Serv, Sagunto, Spain

[2] Hosp Sagunto, Rheumatol Sect, Sagunto, Spain

来源：

ANNALS OF THE RHEUMATIC DISEASES | 2014年 / 73卷

关键词：

D O I：

10.1136/annrheumdis-2014-eular.4919

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

THU0175

引用

页码：241 / 241

页数：1

共 50 条

[1] Etanercept 25 Mg Once Weekly Program For Rheumatoid Arthritis, Psoriatic Arthropathy and Ankylosing Spondylitis Patients In Sustained Clinical and Radiological Remission.
Borras-Blasco, Joaquin
Gracia-Perez, Antonio
Castera, Dolores-Elvira
Dolores Rosique-Robles, J.
Abad, Javier
Gonzalez Alvarez, Alejandro
ARTHRITIS AND RHEUMATISM, 2013, 65 : S207 - S207
[2] Efficacy and safety of adalimumab treatment in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis
Poddubnyy, Denis
Rudwaleit, Martin
EXPERT OPINION ON DRUG SAFETY, 2011, 10 (04) : 655 - 673
[3] CLINICAL AND ECONOMIC IMPACT OF THE USE OF INFLIXIMAB BIOSIMILAR INFLECTRA IN RHEUMATOID ARTHRITIS, PSORIATIC ARTHROPATHY AND ANKYLOSING SPONDYLITIS PATIENTS
Borras Blasco, J.
Gracia-Perez, A.
Castera, D.
Rosique-Robles, D.
Abad, J.
Heskouri Benlemlih, H.
VALUE IN HEALTH, 2016, 19 (07) : A546 - A546
[4] SIGNIFICANT REDUCTION IN BIOLOGIC PRESCRIBING COSTS WHILST MAINTAINING REMISSION IN RHEUMATOID ARTHRITIS, PSORIATIC ARTHRITIS AND ANKYLOSING SPONDYLITIS
Holden, Wendy
RHEUMATOLOGY, 2013, 52 : 146 - 146
[5] PERSISTENCE AND ECON"MIC IMPACT OF ETANERCEPT AND ADALIMUMAB DOSE REDUCTION IN RHEUMATOID ARTHRITIS, PSORIATIC ARTHROPATHY AND ANKYLOSING SPONDYLITIS PATIENTS WITH AT LEAST 1 YEAR IN CLINICAL REMISSION: EXPERIENCE FROM 2 SPANISH TEACHING HOSPITALS DURING 5 YEARS OF FOLLOW-UP
Anton, R.
Navrrao Ruiz, A.
Castera, M.
Jd, R.
VALUE IN HEALTH, 2015, 18 (07) : A643 - A643
[6] Clinical and economic impact of the use of etanercept 25 mg once weekly in rheumatoid arthritis, psoriatic arthropathy and ankylosing spondylitis patients
Borras-Blasco, Joaquin
Gracia-Perez, Antonio
Dolores Rosique-Robles, J.
Elvira Castera, M. D.
Javier Abad, F.
EXPERT OPINION ON BIOLOGICAL THERAPY, 2014, 14 (02) : 145 - 150
[7] Immunogenicity of golimumab and its clinical relevance in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis
Leu, Jocelyn H.
Adedokun, Omoniyi J.
Gargano, Cynthia
Hsia, Elizabeth C.
Xu, Zhenhua
Shankar, Gopi
RHEUMATOLOGY, 2019, 58 (03) : 441 - 446
[8] Demographics and clinical characteristics associated with sustained remission and continuation of sustained remission in patients with rheumatoid arthritis treated with adalimumab
Kimura, Noriko
Suzuki, Katsuya
Takeuchi, Tsutomu
INFLAMMATION AND REGENERATION, 2019, 39 (1)
[9] Demographics and clinical characteristics associated with sustained remission and continuation of sustained remission in patients with rheumatoid arthritis treated with adalimumab
Noriko Kimura
Katsuya Suzuki
Tsutomu Takeuchi
Inflammation and Regeneration, 39
[10] Impact of a Patient Support Program on Abandonment of Adalimumab Treatment Initiation in Patients with Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis
Mease, Philip
Mittal, Manish
Skup, Martha
Davis, Matthew
Ganguli, Arijit
Johnson, Scott
Schiff, Michael
ARTHRITIS & RHEUMATOLOGY, 2016, 68

← 1 2 3 4 5 →